School of Medical Sciences, University of New South Wales, Sydney, NSW 2052, Australia.
School of Population Health, University of New South Wales, Sydney, NSW 2052, Australia.
Medicina (Kaunas). 2022 Aug 14;58(8):1096. doi: 10.3390/medicina58081096.
Background and Objectives: Statins have been extensively utilised in atherosclerotic cardiovascular disease (ASCVD) prevention and can inhibit inflammation. However, the association between statin therapy, subclinical inflammation and associated health outcomes is poorly understood in the primary care setting. Materials and Methods: Primary care electronic health record (EHR) data from the electronic Practice-Based Research Network (ePBRN) from 2012−2019 was used to assess statin usage and adherence in South-Western Sydney (SWS), Australia. Independent determinants of elevated C-reactive protein (CRP) were determined. The relationship between baseline CRP levels and hospitalisation rates at 12 months was investigated. Results: The prevalence of lipid-lowering medications was 14.0% in all adults and 44.6% in the elderly (≥65 years). The prevalence increased from 2012 to 2019 despite a drop in statin use between 2013−2015. A total of 55% of individuals had good adherence (>80%). Hydrophilic statin use and higher intensity statin therapy were associated with elevated CRP levels. However, elevated CRP levels were not associated with all-cause or ASCVD hospitalisations after adjusting for confounders. Conclusions: The prevalence and adherence patterns associated with lipid-lowering medications highlighted the elevated ASCVD-related burden in the SWS population, especially when compared with the Australian general population. Patients in SWS may benefit from enhanced screening protocols, targeted health literacy and promotion campaigns, and timely incorporation of evidence into ASCVD clinical guidelines. This study, which used EHR data, did not support the use of CRP as an independent marker of future short-term hospitalisations.
他汀类药物已广泛用于动脉粥样硬化性心血管疾病(ASCVD)的预防,并具有抗炎作用。然而,在基层医疗环境中,他汀类药物治疗、亚临床炎症及其相关健康结局之间的关系仍知之甚少。
利用澳大利亚西南悉尼(SWS)电子实践为基础的研究网络(ePBRN)的电子健康记录(EHR)数据,评估 2012 年至 2019 年 SWS 地区他汀类药物的使用情况和用药依从性。确定了 C 反应蛋白(CRP)升高的独立决定因素。分析了基线 CRP 水平与 12 个月内住院率之间的关系。
所有成年人降脂药物的患病率为 14.0%,老年人(≥65 岁)的患病率为 44.6%。尽管在 2013-2015 年期间他汀类药物的使用有所下降,但 2012 年至 2019 年期间这一比例仍在上升。共有 55%的个体具有良好的用药依从性(>80%)。亲水他汀类药物的使用和高强度他汀类药物治疗与 CRP 水平升高有关。然而,在校正混杂因素后,升高的 CRP 水平与全因或 ASCVD 住院无关。
降脂药物的流行率和用药依从性模式凸显了 SWS 人群 ASCVD 相关负担的增加,特别是与澳大利亚普通人群相比。SWS 的患者可能受益于强化筛查方案、有针对性的健康素养和宣传活动,以及及时将证据纳入 ASCVD 临床指南。本研究使用 EHR 数据,不支持 CRP 作为未来短期住院的独立标志物。